Garden State hoping to bloom into Australia’s medical cannabis capital

|

Published 01-FEB-2019 16:15 P.M.

|

4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

If, like me, you have a fiery aversion to Racing Carnival season, sportsball, Soviet Russia-style winters, and Clive Palmer's marketing campaign, fear not. Victoria has high hopes to blossom into the medicinal cannabis heartland of Australia.

Last year, Victoria released Australia’s first-ever medicinal cannabis industry development plan, mapping out a framework for government support of the fast-growing industry.

The strategy aims to have the state supply half of Australia’s pot by 2028, along with the creation of 500 local jobs.

Victoria was the first state to legalise the use of medicinal cannabis in 2016, but only for patients in exceptional circumstances, such as children with epilepsy.

Last April, Canada's Canopy Growth (NYSE:CGC | TSX:WEED), the world's biggest medicinal cannabis company, said it will spend some $16 million establishing a hub for cultivation and production in Victoria, with a long-term view of exporting the product overseas.

ASX pot-stocks like Cann Group (ASX:CAN), which is building Australia’s largest state-of-the-art medicinal cannabis growing facility near Melbourne Airport, as well as THC Global (ASX:THC), are already establishing Victorian operations to supply both local and international demand.

This week, two Canadian companies revealed plans to invest in Victoria as a would-be hash hub.

Cronos Australia, a subsidiary of the Canadian Cronos Group (TSE:CRON | NASDAQ:CRON), unveiled its intention to locate its Asia-Pacific headquarters in Victoria, along with a state-of-the-art research and development centre and production facility.

The new facility will strengthen the quality and efficacy of cannabinoid-based products for both domestic and international patients as market opportunities grow.

On top of that, fast-growing startup, Cannatrek, an investee of Ontario-based CannTrust (TSE:TRST), will invest $30 million to expand its production and manufacturing capacity in Victoria and create up to 75 new jobs in Shepparton and La Trobe University.

Cannatrek is also working towards a research and education partnership with La Trobe.

Nearly all medicinal cannabis in Australia is imported, making access to the drug prohibitive for many. However, local businesses like Cannatrek are aiming to make the product more affordable.

The company is currently supplying weed from Canadian sources, and has set up a research facility in Brisbane.

It will begin to build a 160,000-square-metre greenhouse facility in Shepparton later this year. Cannatrek chief executive, Tommy Huppert, believes the industry can create thousands of jobs across Australia.

Huppert said Shepparton’s climate and horticultural history is highly suited to the production of medicinal cannabis, suggesting the new facility would be located outdoors.

‘‘Regional Victoria is blessed with abundant daylight, possessing the ideal climate for growing this valuable medicinal resource,’’ Huppert said. ‘‘Cannatrek is grateful for the opportunity to pioneer this industry.’’

Newly installed agriculture minister and legislative council member for Northern Victoria, Jaclyn Symes, said the growth of a medicinal cannabis industry in regions such as Shepparton was part of the Andrews Government’s long-term medicinal cannabis strategy.

Symes noted that in hosting Cronos Australia's Asia-Pacific R&D centre alongside Spectrum Cannabis Australia and Cann Group's medicinal cannabis operations, Victoria is quickly cementing its position as the southern hemisphere's hub for cultivation and production of high-quality medicinal cannabis products.

Yet Victoria’s ambition to emerge as the pot capital of Australia is not likely to be successful unless market access for local patients significantly improves.

Despite considerable improvements over the past year, patient access to medical cannabis remains a considerable concern, and has been described as a bureaucratic nightmare to navigate for those who need it the most.

“The crux of the problem is, we can’t produce medical cannabis products for our market unless we enable the market [patients] to access those products,” Fiona Patten, leader of the Reason Party and a member of the Legislative Council for Victoria, told Marijuana Business Daily.

“Without broader patient approval, we won’t get a production industry off the ground.”

As of the end of 2018, Australia’s Therapeutic Goods Administration approved just over 2,800 patients throughout the country from 54 authorised prescribers. According to Patten, that accounts for just 3% of the people who should qualify for medical cannabis use in the country.

For Patten, Victoria’s aim to be a leader in medical cannabis exports is also a “kick in the gut to very sick Victorians who could benefit from this product” but who struggle with access and prohibitive costs.

The legal medical cannabis market in Australia is currently valued at $17.7 million annually, and could be worth $1.2 billion by 2024, ramping up to $3 billion by 2028, according to market intelligence firm, Prohibition Partners.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X